Could a Chemo-Immunotherapy combo beat standard care for tough lung cancer?
NCT ID NCT05856695
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a chemotherapy combination without etoposide (carboplatin plus paclitaxel) plus the immunotherapy drug durvalumab works better than standard treatment for people with extensive-stage small cell lung cancer. About 67 participants will receive the drugs to see if it improves overall survival. The goal is to find a more effective first-line option for this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carboplatin, paclitaxel, and durvalumab (a type of immunotherapy)
What this could lead to
If successful, this could point toward a more effective first-line treatment for extensive-stage small cell lung cancer, potentially improving survival.
What could go wrong
This is a small, early-phase (phase 2) proof-of-concept study with only 67 participants. The combination may not prove superior to standard therapy, and side effects from chemotherapy and immunotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abbeville - CH
Abbeville, France
-
Amiens - Clinique de l'Europe
Amiens, France
-
Angers - CHU
Angers, France
-
Annemasse - CH
Contamine-sur-Arve, France
-
Besançon - CHU
Besançon, France
-
Bordeaux - CHU
Bordeaux, France
-
Boulogne - Ambroise Paré
Boulogne-Billancourt, France
-
CHU Montpellier
Montpellier, 34295, France
-
CHU Toulouse
Toulouse, 31059, France
-
Caen - CHU Côte de Nacre
Caen, 14000, France
-
Chambéry - CH
Chambéry, France
-
Cholet - CH
Cholet, France
-
Colmar - CH
Colmar, France
-
Créteil - CHI
Créteil, France
-
Dijon - CHU Bocage
Dijon, France
-
Grenoble - CHU
Grenoble, France
-
Le Mans - CHG
Le Mans, France
-
Lyon - URCOT
Lyon, France
-
Marseille - APHM
Marseille, France
-
Marseille - Hôpital Européen
Marseille, France
-
Morlaix - CH
Morlaix, France
-
Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
-
Orléans - CHR
Orléans, France
-
Paris - Bichat
Paris, France
-
Paris - Hôpital Cochin
Paris, France
-
Paris - Tenon
Paris, France
-
Rennes - CHU
Rennes, France
-
Toulon - Sainte Anne HIA
Toulon, France
-
Tours - CHU
Tours, France
-
Vandoeuvre-lès-Nancy - CRLCC
Vandœuvre-lès-Nancy, France
-
Villefranche sur Saône - CH
Villefranche-sur-Saône, France